



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

Daily 20.IX.2022

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
BioMaxima	Not rated	37.1	Not rated	Sylvia Jaśkiewicz, CFA Mikołaj Stępień, Michał Zameł

Event: Vital contract signed

Yesterday, before the trading session, BioMaxima informed about a new contract for a sale of and delivery of an analyzer for cell cultures monitoring signed with a Polish pharmaceutical company. The contract is worth c. PLN 1 million and will be realized in October this year. An annual revenue generated on this contract will reach PLN 0.5 million as BioMaxima will have to provide the company with necessary chemical reagents and consumables.

Expected impact: *Positive information*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.